Accenture CEO Julie Sweet diagnosed with breast cancer; expects to continue leading company during treatment

Accenture plc

Diagnosis caught early; prognosis 'excellent' and condition curable; PET scan shows no cancer elsewhere.
Surgery next week; expected treatment includes radiation lasting 12 to 16 weeks.
Sweet says she will work 'substantially as normal' leading day-to-day operations throughout treatment; will curtail travel.
Board has been briefed and is fully supportive; Global Management Committee will support operations.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.